Study Evaluation Tazocin Intervention

Wyeth is now a wholly owned subsidiary of Pfizer134 enrolled

Overview

This is an antibiotic intervention study to determine the value of using piperacillin/tazobactam in reducing the cases of ESBL producing E. coli or K. pneumoniae colonization and infection.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

HEALTH_SERVICES_RESEARCH

Masking

NONE

Enrollment

134

Conditions

Bacterial Infections

Interventions

Tazocin (pipercillin/tazobactam)DRUG

over 50% third generation cephalosporin should be replaced by Pip/Taz

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * All patients admitted or transferred to ICU/Pulmonary units * Patients of either sex, 18 years of age or older Exclusion Criteria: \- Patients who stay in units less than 48 hours will not be enrolled.

Locations (1)

Unnamed facility

Beijing, Beijing Municipality, China

Outcomes

Primary Outcomes

1. The acquisition rate of ESBL producing E. coli or K. Pneumoniae at the end of phase I (pre-intervention) and phase II (last 3 months of intervention phase)

Time frame: 9 months

Secondary Outcomes

The infection rate due to ESBL producing E. coli or K. pnumoniae at the end of phase I (pre-intervention) and phase II (last 3 months of intervention phase)

Time frame: 9 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.